These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1047 related items for PubMed ID: 16104900

  • 1. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M.
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [Abstract] [Full Text] [Related]

  • 2. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV.
    Cancer; 2006 Aug 01; 107(3):514-20. PubMed ID: 16795068
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 01; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 10. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.
    Can J Urol; 2007 Jun 01; 14(3):3551-9. PubMed ID: 17594745
    [Abstract] [Full Text] [Related]

  • 11. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun 01; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 12. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 13. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
    Copp H, Bissonette EA, Theodorescu D.
    Urology; 2005 Jun 01; 65(6):1146-51. PubMed ID: 15922433
    [Abstract] [Full Text] [Related]

  • 14. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.
    BJU Int; 2006 Jun 01; 97(6):1184-9. PubMed ID: 16686709
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H.
    Int J Urol; 2006 Dec 01; 13(12):1494-500. PubMed ID: 17118024
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H, Katayose K, Kumakawa K, Shiraiwa Y, Uchida H, Takahashi Y, Yazaki J, Yamaguchi O.
    Gan To Kagaku Ryoho; 2005 Jan 01; 32(1):57-63. PubMed ID: 15675583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.